期刊
MEDICAL ONCOLOGY
卷 25, 期 4, 页码 374-379出版社
HUMANA PRESS INC
DOI: 10.1007/s12032-008-9049-z
关键词
Rituximab; Maturation arrest; Neutropenia; Lymphoma; HAX1; Granulopoiesis
类别
资金
- Swedish Society for Medical Research
- Swedish Cancer Foundation
- Roche Pharmaceutical
- Stockholm County Council
Late-onset neutropenia, i.e. an absolute neutrophil count of < 1.5 x 109/l, may follow 4 weeks or more after therapy with rituximab for lymphoma. However, incidence, predisposing factors, and pathogenic mechanisms are still poorly defined. In a retrospective study of 113 consecutive lymphoma patients treated with rituximab, with or without chemotherapy, we found eight patients (7%) with late-onset neutropenia (LON). Median time to onset was 88 days (range, 1-9 months) after last rituximab dose. Median duration of LON was 54 days (range, 1-17 weeks). Four of the eight patients underwent stem cell transplantation. Three patients developed febrile neutropenia and two required treatment with granulocyte colony-stimulating factor. In four subsequently identified patients with severe LON, a maturation arrest at the (pro)myelocyte stage was observed in the bone marrow, similar to that found in severe congenital neutropenia or Kostmann disease. However, none carried mutations in HAX1, thus ruling out such mutations in the development of the maturation arrest in these patients. Nevertheless, our data suggest that rituximab-related LON and congenital neutropenia might share similar neutropenia-causing mechanisms resulting in maturation arrest.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据